Reports
Subscribe to
our newsletters!
Showing 21–40 of 54 resultsSorted by latest
-
On the same day of purchaseThis product provides basic information on immunotherapy candidates in research and development targeting DLL3.€ 200.00
-
On the same day of purchaseThis product provides basic information on immunotherapy candidates in research and development targeting B7-H3.€ 300.00
-
On the same day of purchaseThis product provides basic information on antibody therapy candidates in R&D targeting EpCAM.€ 200.00
-
On the same day of purchaseThis product provides basic information on antibody therapy candidates in R&D targeting PD-1.€ 200.00
-
On the same day of purchaseThis product provides basic information on antibody therapy candidates in R&D targeting c-Met.€ 300.00
-
On the same day of purchaseThis product provides basic information on immunotherapy candidates in research and development targeting mesothelin€ 300.00
-
On the same day of purchaseThis product provides basic information on therapeutic antibodies in R&D targeting C-C chemokine receptor type 8 (CCR8).€ 300.00
-
On the same day of purchaseThis product provides basic information on drug candidates in research and development targeting CD40 or CD40 ligand€ 300.00
-
On the same day of purchaseThis product provides basic information on drug & imaging candidates in R&D targeting Fibroblast Activation Protein (FAP)€ 300.00
-
On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D targeting folate receptor alpha (FRα)€ 300.00
-
On the same day of purchaseThis product provides basic information on approved drugs and immunotherapy candidates in R&D targeting IGF-1 or its receptor (IGF-1R)€ 300.00
-
August of 2023This report provides a landscape description and analysis of discovery and development of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates from an industry perspective as of August 2023Original price was: € 2150.00.€ 1720.00Current price is: € 1720.00.
-
July of 2023This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
-
March of 2023Sales data of originator therapeutic proteins and antibodies & selected biosimilar antibodies and proteins and other biologics in 2022€ 120.00
-
February of 2023This report provides a landscape description and analysis of CAR-M platform technologies and stakeholders from an industry perspective as of February 2023€ 1800.00
-
November of 2022This report provides a landscape description and analysis of discovery and development of novel drug modalities targeting RNA from an industry perspective as of November 2019.€ 2350.00
-
July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.Original price was: € 2550.00.€ 1800.00Current price is: € 1800.00.
-
July of 2022The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00
-
June of 2022The report evaluates opportunities for ROR1-targeted drug modalities within the competitive landscape€ 1050.00
-
May of 2022This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00